Tampilkan postingan dengan label Democrats. Tampilkan semua postingan
Tampilkan postingan dengan label Democrats. Tampilkan semua postingan

Rabu, 13 September 2017

Dueling visions of health care policy

Today's Managing Health Care Costs Number is 30 million


Two competing health plans have been in the news today. Bernie Sanders has rolled out his "Medicare for All" plan, and the Lindsey Graham Bill Cassidy proposal has gained new "moderate" support and will be yet another Republican attempt to repeal Obamacare.

First, the Republican plan.   David Leonhart titled his post on this "New TrumpCare Deserves a Quick Death." He points out that although the sponsors claim that this bill would allow states freedom to innovate - it would rapidly decrease the available funds.  Even states committed to universal health care access might be hacking away at the number of those with subsidized insurance very quickly.  The Congressional Budget Office hasn't weighed in yet -but this bill is close enough to past TrumpCare bills that he estimates it would lead to 15 million additional uninsured in 2018, and 30 million losing insurance over the next decade.

It's hard to say that Graham-Cassidy absolutely won'tpass, and it would be a deeply disruptive bill that would make health care in the US much worse than it currently is.  The more time Congress spends on that bill, the less effort it will put into the market fixes we so desperately need for the Affordable Care Act.

With great fanfare, Bernie Sanders has introduced his Medicare for All plan today.   He has 17 cosponsors in the Senate (he had none when he introduced his last universal health care bill), and about 60% of House Democrats have endorsed a different universal health care bill.   The Sanders approach is aspirational - In an interview with Vox, he says:

I mean, this is a big issue, and we are introducing comprehensive legislation at a time when we have Donald Trump as president, who wanted to throw 32 million people off the health insurance. You know, Mitch McConnell, Paul Ryan, running the Senate and the House. We're not going to get this thing done with these guys in power.

Sarah Kliff has a summary of the details of the Sander's plan.   The initial plan was explicit about benefits and cost sharing (rich benefits for all, no substantial cost sharing for patients) and mum on costs; this afternoon he released additional details including a 7.5% employer payroll tax exempting small businesses (that's much less than most employers spend on health coverage), and a 4% income tax on individuals exempting low income people. For many, this would be a good deal.

And that's the problem.   If Sanders is able to provide insurance for all with close to no cost sharing (which means there will be more discretionary utilization), it's either going to cost more (much more, as California discovered) or providers will be paid much less.  The Sanders plan would create a national fee schedule (Medicare), but would increase payment to providers caring for Medicaid beneficiaries.   The decline in provider reimbursement would have to be huge to provide enough savings to make this work.

We need meaningful reform of the health care system - and we need lower unit prices.  There will be plenty of time to evaluate whether the Sanders plan is the best way to get to universal access - and I'm in favor of modest cost sharing as opposed to no cost sharing at all.  Today lets us all see the vision of each party -- one is satisfied to leave 30 million additional Americans uninsured; the other wants to insure everyone, but there is a danger that this is the "unicorn" plan in that it is rooted in fiction in that it might not be affordable.




Senin, 07 Agustus 2017

Bringing down pharmaceutical costs

Bringing down pharmaceutical costs


Today's Managing Health Care Costs Number is  250%

One area of bipartisan agreement is the desire to lower pharmaceutical prices.   As always, there are good ideas with downsides, bad ideas with upsides, and many ideas that are likely to  have unanticipated consequences.   Annual prescription drug costs are expected to increase to $597 billion by 2025- a 250% increase from 2007, so there is a real imperative to address pharmaceutical costs. 

Among the ideas that are being discussed:

  1. Ease regulatory burden to allow faster generics to market. 
    The real problem here has generally been litigation from incumbent brand name products and lack of competition for non-blockbuster generics, most of which have only 1 or 2 manufacturers - leaving them vulnerable to steep price increases.  Let's make it harder to take legal steps to block new generics, easier to get approval for biosimilars, and allow importation of generics from other countries with good regulatory schemes when there is a shortage.
     
  2. Allow 'value based pricing.'
    No one is preventing value based pricing now- but we should think hard about whether this is really what we want.   Airlines use value based pricing (so that business travelers not staying over a Saturday night pay higher prices).   Some pharmaceutical companies want to be able to charge different prices based on the indication for a drug - but this is likely to lead to higher overall costs (and huge administrative headaches).  Her's a pretty positive assessment of  indication specific pricing from ICER (2015), and here's a perspective from New England Journal of Medicine (2017) pointing to likely higher overall costs. Reports from countries that implemented warrantees are disappointing; these were hard to reconcile and probably led to higher prices. A report from Propublica  begins:

More than a decade ago, Italy tried a novel approach to help bring down drug costs: asking pharmaceutical companies to return money to the national health system if some of their medicines failed to work as expected. The effort largely flopped

  1. "March in" and demand that patent-holders offer drugs for less, or seize the patent
    Some countries like Brazil and India have effectively done this- but they are much smaller markets than the US and they tend to be home to generic and not brand manufacturers.   This might be a more effective threat than actual policy.  Some Democrats have suggested that the NIH should exercise its 'march in' rights. Many think this would lead to decreased investment in pharma and less innovation - and such a move seems unlikely in an Administration seeking to diminish the role of government.
     
  2. Allow Medicare to negotiate drug prices
    Right now Medicare Part D is administered through thousands (!) of different plans each of which negotiates with the pharmaceutical industry.  That kind of fragmentation leads to higher prices for Medicare, the largest purchaser of drugs in the country.   Medicare pays more than the Veterans Administration or Medicaid for drugs.  It's hard to imagine disassembling the current Medicare Part D system in the next few years - although it would be easy to imagine some central negotiation for high cost medications that could be excluded from the Medicare Part D plans.
     
  3. Stop drug company direct to consumer advertising
    This would make TV viewing much more pleasurable - but the Supreme Court has decided that commercial speech is protected by the First Amendment, so this would require a constitutional amendment.
     
  4. Direct the FDA to consider cost effectiveness when it approves new medications
    This would require a new statute and new enabling regulations. Countries like the UK which have this in place have found that it does lower access to some new innovative drugs, and this is unpopular.  Perhaps this isn't unpopular at the level of fictional "death panels," but it would be hard to see such legislation gaining broad traction in the next few years.
     
  1. Mandate generic substitution
    Fourteen states mandate that a generic be dispensed where available unless the physician explicitly orders a brand name, and this dramatically increases generic substitution rate.  49 states allow pharmacist generic substitution based on pharmacist discretion - and only Oklahoma prohibits even this.  This battle must be fought state by state, and a small amount of lobbying goes a long way in most state legislatures.
     
  1. Provider risk sharing
    Physicians write prescriptions - and they would pay much more attention to the cost of drugs if their organizations bore financial responsibility for drug costs.  Providers do take risk for drug spending in some accountable care or bundled payment arrangements.  Provider risk sharing could also lead to physicians failing to prescribe valuable but expensive drugs, or "dumping" of patients with known chronic diseases that have expensive drug treatment. 

I'm not confident we'll lower pharmaceutical prices a lot over the next few years- especially given the new genomic drugs in the offing.  And I'm worried that the cost savings from generics might diminish through consolidation in that industry. But I'm heartened by the discussion and the bipartisan concern. Elements of the approach to lowering drug cost inflation that are being discussed now could serve as the foundation to lower costs in the years to come.
  

Jumat, 14 Juli 2017

Compromise is hard when there is no agreement about goals

Compromise is hard when there is no agreement about goals


Today's Managing Health Care Costs Number is 4
 

The new revised  Republican Senate health care bill is worse than the last iteration of the Better Care Reconciliation Act.
 
  • It will still cause devastating cuts in Medicaid - an incredibly valuable program that finances delivery for 45% of deliveries, 60% of nursing home stays and a substantial portion of the costs of substance abuse treatment.  
  • It is worse in that it allows insurance plans to sell non-compliant health plans - and allows the healthy to use health savings accounts or federal subsidies to purchase these skimpy plans.  That will lead to even more of the young and healthy skipping out of comprehensive health plans -and price more of the old and sick out of the market
  • It adds a little to subsidies for the near-poor - but not enough for most of them to be able to purchase health insurance that has affordable premiums and out of pocket costs that are income-appropriate
  • It puts an inadequate amount into high risk pool funding - and distributes this to the states, which historically have failed at setting up effective high cost pools
  • It puts some dollars into opioid programs, but decimating the Medicaid program will offset the good that comes from this.
  • It would allow many Americans to be in health plans that would not cover essential benefits - so that the funding for those benefits would be threatened for those who need them.
  • Separate Republican bills would prohibit the IRS from enforcing the individual mandate, which would further erode the health of those in the exchange and lead to higher prices and potential "death spiral."

A group of Democratic House members have put forward their plan to "fix" Obamacare.   This bill is thoughtful and would represent a real step forward.   It includes

  • Commitment to paying the cost sharing reductions going forward
  • Higher amount of subsidies to attract the healthy to the exchange markets, with aggressive marketing and potentially changing the open enrollment cycle to tax refund season
  • Enforcement and potential increase in the individual mandate penalties
  • Permanent reinsurance fund to protect health plans from the costs of enrolling the highest risk members
  • An ill-defined mechanism to allow older pre-65 Americans to "buy into" Medicare, which would also help take some of the most expensive patients off the individual exchange markets.

What's striking about these two efforts is that there is essentially no overlap. The Republicans seek to decrease taxes (on the rich) and decrease the role of the government in both financing and regulating health care, even though the US health care system is a failed experiment in leaving the system to only a very lightly regulated market in the eyes of many economists.  The Democrats want to insure affordable access to health care for all - and are willing to do this by increasing the role of government - even though all those with current levers of power adamantly oppose this and are ideologically and politically committed to moving in the opposite direction.  

It's really hard to compromise when there is no overlap in what each party is looking for!

I've been thinking hard about where there could be room for compromise, and frankly, I don't see much.   A few preliminary thoughts:

Concept
Party Positions
Challenge
Decrease regulations that prevent less expensive practitioners from providing services
Republicans are often against regulations - and these are regulations that genuinely could increase market effectiveness
The doctor, dentist, and even nurse lobbies are adamantly opposed and claim that these regulations protect consumers.
 
Further, these are largely state regulations, and federal preemption of state regulation is fraught with problems
Increase enforcement of antitrust laws, as provider consolidation is a major reason for unit cost increases
Democrats in general are more supportive of antitrust enforcement; Republicans are more likely to worry about government interference
Providers have a huge amount of political influence, and oppose such enforcement
Offer national reinsurance  at a low attachment point, so that the care beyond $50 or $75,000 annually would be the responsibility of the federal government
Republicans are putting tens of billions into high risk pools -although they would likely be loathe to use these funds for a federal program.  
 
Democrats have proposed this before (Kerry 2004 health care plan).

This could also help decrease risk selection in health plans, and would be a relief to employers who struggle with high cost cases. 
Insurance companies (and reinsurers) would not necessarily like losing this portion of their current business.

Ideally the federal government would have the states administer this through their existing Medicaid non-managed care contracts, and could fund this 100% to avoid state rejection
Increase funding for anti-fraud efforts
These pay for themselves, and no one is in favor of fraud and abuse!
Some will again worry of government overreach, and the Trump Administration is in the process of disassembling regulatory apparatus.

Some of the more extravagant claims of fraud include simple coding errors (like a woman being miscoded as a male and then a delivery being considered "fraud").

There is a ceiling of potential savings - though we are nowhere close to that yet.
 




That's all I've got. Just four rows.   It's not much to work off of - and none of these are slam-dunks.  This highlights just how hard it will be to develop a compromise in these polarized times.